Department of Epidemiology, University of Washington, Seattle, WA, USA.
Departments of Biostatistics and Global Health, University of Washington, Seattle, WA, USA.
BJOG. 2022 May;129(6):926-937. doi: 10.1111/1471-0528.17032. Epub 2022 Jan 18.
To determine the contribution of specific contraceptive side effects to method switch and modern-method discontinuation among Kenyan women.
A prospective cohort study.
Five counties in Western Kenya.
Women aged ≥18 years old and emancipated female minors ≥14 years old using modern, reversible contraception were recruited while attending 10 public health facilities.
Patient-reported adverse effect symptoms, method switch and discontinuation were reported through weekly text message-based surveys for 24 weeks.
Prevalence, hazards ratio (HR).
Among 825 women, 44% were using implants, 43% injectables, 7% an intrauterine device and 6% oral contraceptive pills at enrolment. Most (61%) women were continuing a method used in the previous month. During the 24-week follow up, incidence of contraceptive switch was 61.3 per 100 person-years (95% confidence interval [CI] 52.4-71.8) and incidence of discontinuation was 38.5 per 100 person-years (95% CI 31.6-47.0). On average, one-quarter (prevalence [Pr] 0.24, 95% CI 0.22-0.26) of participants reported side effects or method problems weekly, with sexual side effects the most prevalent symptom (Pr 0.15, 95% CI 0.13-0.16). Lack of expected bleeding was associated with higher risk of method switch (adjusted hazard ratio [aHR] 2.36, 95% CI 1.22-4.57). Risk of all-modern method discontinuation was higher among women experiencing irregular bleeding (aHR 2.39, 95% CI 1.20-4.77), weight changes (aHR 2.72, 95% CI 1.47-4.68) and sexual side effects (aHR 2.42, 95% CI 1.40-4.20).
Addressing irregular bleeding, weight changes and sexual side effects through development of new products that minimise these specific side effects and anticipatory counseling may reduce method-related discontinuation.
Bleeding, weight changes, sexual problems associated with discontinuation of #contraception, but many continue despite side effects.
确定肯尼亚妇女特定避孕副作用对方法转换和现代方法停用的贡献。
前瞻性队列研究。
肯尼亚西部的五个县。
招募年龄≥18 岁且已成年的女性和≥14 岁的女性未成年使用现代、可逆避孕措施时,在 10 个公共卫生设施就诊。
通过每周基于短信的调查报告患者报告的不良反应症状、方法转换和停药情况,为期 24 周。
患病率、危害比(HR)。
在 825 名女性中,44%使用植入物,43%使用注射剂,7%使用宫内节育器,6%使用口服避孕药。大多数(61%)女性继续使用前一个月使用的方法。在 24 周的随访期间,避孕方法的转换发生率为每 100 人年 61.3 例(95%置信区间 [CI] 52.4-71.8),停药发生率为每 100 人年 38.5 例(95% CI 31.6-47.0)。平均而言,四分之一(患病率 [Pr] 0.24,95% CI 0.22-0.26)的参与者每周报告副作用或方法问题,性副作用是最常见的症状(Pr 0.15,95% CI 0.13-0.16)。缺乏预期出血与方法转换风险增加相关(调整后的危害比 [aHR] 2.36,95% CI 1.22-4.57)。经历不规则出血的女性发生所有现代方法停药的风险更高(aHR 2.39,95% CI 1.20-4.77)、体重变化(aHR 2.72,95% CI 1.47-4.68)和性副作用(aHR 2.42,95% CI 1.40-4.20)。
通过开发新产品来解决不规则出血、体重变化和性问题,这些问题会最小化这些特定的副作用,并通过预期咨询来减少与方法相关的停药。
与避孕措施停用相关的出血、体重变化和性问题,但许多人尽管有副作用仍继续使用。